-
Mashup Score: 6BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors - 5 hour(s) ago
The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
Co-formulated vibostolimab and pembrolizumab plus chemotherapy failed to improve OS in the first line vs atezolizumab plus chemotherapy in ES-SCLC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC @danafarber @SITCancer #SITC2024 #oncology https://t.co/VQUow6vbS0
-
-
Mashup Score: 0
The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors @TheSTARTCenter @SITCancer #SITC2024 #oncology https://t.co/lbPAU2lPxU
-
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors @TheSTARTCenter @SITCancer #SITC2024 #oncology https://t.co/lbPAU2lPxU